What’s the current market cap for Ligand Pharmaceuticals stock?

Ligand Pharmaceuticals (LGND) has a market cap of $4.6B as of May 25, 2026.

What is the P/E ratio for Ligand Pharmaceuticals stock?

The price to earnings (P/E) ratio for Ligand Pharmaceuticals (LGND) stock is 30.58 as of May 25, 2026.

Does Ligand Pharmaceuticals stock pay dividends?

No, Ligand Pharmaceuticals (LGND) stock does not pay dividends to its shareholders as of May 25, 2026.

When is the next Ligand Pharmaceuticals dividend payment date?

Ligand Pharmaceuticals (LGND) stock does not pay dividends to its shareholders.

What is the beta indicator for Ligand Pharmaceuticals?

Ligand Pharmaceuticals (LGND) has a beta rating of 1.07. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Ligand Pharmaceuticals stock | $LGND Share Price

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

Ticker

$LGND

Sector

Health

Primary listing

NASDAQ

Employees

47

Headquarters

Jupiter, United States

Website

www.ligand.com

LGND Metrics

BasicAdvanced

$4.6bn

30.58

$7.50

1.07

-

What the Analysts think about LGND

Analyst ratings (Buy, Hold, Sell) for Ligand Pharmaceuticals stock.

Bulls say / Bears say

Ligand’s Q1 2026 royalty revenue surged 56% year-over-year to $43.0 million, driven by contributions from Filspari, Ohtuvayre, and Capvaxive, highlighting strong growth of its core royalty portfolio. (GlobeNewswire)

The definitive $739 million acquisition of XOMA Royalty for $39 per share, covering over 120 commercial, clinical, and preclinical assets, enabled management to raise 2026 total revenue guidance to $270 million–$310 million. (GlobeNewswire)

As of March 31, 2026, Ligand held $779.4 million in cash and short-term investments, with nearly $1 billion of available capital to support its strategy of investing $150 million–$250 million annually in high-value royalty assets. (GlobeNewswire)

Q1 2026 total revenue of $51.7 million missed consensus estimates of $59.07 million by 12.44%, underscoring the risk of forecast variability in its royalty-driven model. (Investing.com)

Captisol sales declined to $8.7 million in Q1 2026 from $13.5 million a year earlier due to timing of customer orders, raising concerns about the stability of its materials revenue stream. (GlobeNewswire)

Ligand reported a GAAP net loss of $13.3 million in Q1 2026, driven by a $49.2 million non-cash fair value loss on its Pelthos investment, highlighting significant non-operating income volatility. (GlobeNewswire)

Data summarised monthly by Lightyear AI. Last updated on 19 May 2026.

LGND Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

LGND Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

LGND News

AllArticlesVideos

Ligand Pharmaceuticals Q1 Earnings Call Highlights

MarketBeat·2 weeks ago

XOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMA

Business Wire·4 weeks ago

Ligand Bets On Royalty Growth With XOMA Buyout Worth Over $700 Million

Benzinga·4 weeks ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

About Ligand Pharmaceuticals

Ticker

Employees

LGND Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about LGND

Analyst Ratings

Bulls say / Bears say

LGND Financial Performance

Income Statement

LGND Earnings Performance

Earnings per share (EPS)

LGND News

Ligand Pharmaceuticals Q1 Earnings Call Highlights

XOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMA

Ligand Bets On Royalty Growth With XOMA Buyout Worth Over $700 Million

Buy $LGND

Upcoming events

No upcoming events

Lightyear

Legal

Work with us

Bulls say / Bears say

Ligand Pharmaceuticals/$LGND

About Ligand Pharmaceuticals

Ticker

Employees

LGND Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about LGND

Analyst Ratings

Bulls say / Bears say

LGND Financial Performance

Income Statement

LGND Earnings Performance

Earnings per share (EPS)

LGND News

Ligand Pharmaceuticals Q1 Earnings Call Highlights

XOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMA

Ligand Bets On Royalty Growth With XOMA Buyout Worth Over $700 Million

Buy $LGND

Upcoming events

No upcoming events

What’s the current market cap for Ligand Pharmaceuticals stock?

What is the P/E ratio for Ligand Pharmaceuticals stock?

Does Ligand Pharmaceuticals stock pay dividends?

When is the next Ligand Pharmaceuticals dividend payment date?

What is the beta indicator for Ligand Pharmaceuticals?

Bulls say / Bears say